Light­stone Ven­tures un­veils $375M third fund, this time ex­pand­ing its wish­list in blos­som­ing CNS field

Neu­ro­science is hav­ing a mo­ment right now, and one VC firm strad­dling the line be­tween biotech and medtech is look­ing to cap­i­tal­ize on the field’s rapid growth.

Light­stone Ven­tures has raised $375 mil­lion for its third ven­ture fund with an eye on ex­pand­ing its fo­cus in CNS dis­ease, the firm said Tues­day.

The newest raise brings Light­stone’s to­tal to more than $850 mil­lion since the firm was found­ed back in 2012. So far, that trea­sure chest has led to in­vest­ments in around 30 com­pa­nies split across the biotech and medtech spaces. With its third and largest fund, Light­stone is ex­pect­ing much the same as be­fore — most­ly in­vest­ments in seed-stage to Se­ries A com­pa­nies with an eye on “break­throughs” in pa­tient care, gen­er­al part­ner Ja­son Lettmann told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER